• Mineralys Therapeutics director Daphne Karydas sold 3,000 common shares at USD 28.58 on Sep. 15, 2026.
• She exercised stock options for 3,000 shares at USD 12.02 in a same-day transaction.
• Directly held common stock position fell to 6,200 shares following the trades.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001816952-26-000005), on September 17, 2026, and is solely responsible for the information contained therein.